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A conceptual design for artiﬁcial antimicrobial viruses is described. The design emulates viral assembly
and function to create self-assembling peptide capsules that promote eﬃcient gene delivery and
silencing in mammalian cells. Unlike viruses, however, the capsules are antimicrobial, which allows
them to exhibit a dual biological function: gene transport and antimicrobial activity. Unlike other
antimicrobials, the capsules act as pre-concentrated antimicrobial agents that elicit rapid and
localised membrane-disrupting responses by converting into individual pores at their precise landing
positions on membranes. The concept holds promise for engineering virus-like scaﬀolds with
biologically tuneable properties.Introduction
The rise of antimicrobial resistance presents new challenges
for supramolecular chemistry and design. A key driver here is
the demand for smaller, non-toxic and biologically diﬀerential
materials.1 This is particularly important for molecular
therapy, which depends on adaptable nanoscale vehicles to
safely handle and deliver therapeutic nucleic acids into
human cells.2 However, gene delivery can be compromised by
bacterial infections, which prompts the need for vehicles with
antimicrobial properties.3 Viruses may be the most eﬃcient
gene-transfecting agents, but typically are not antimicrobial.
Similarly, non-viral mimetics can emulate encapsulating and
cell-penetrating properties of viruses, but lack the ability to
selectively diﬀerentiate between bacterial and mammalian
cells.4 A saving solution to this can come from virus-like
assemblies of antimicrobial components that would induce
localised toxic responses on binding to microorganisms. The
innate immune system oﬀers a rich repertoir of such compo-
nents.5 Unlike conventional antibiotics, these are host-defense
polypeptide sequences that recognise microbial surfaces,
bind to them and at critical concentrations assemble into
membrane-disrupting pores or channels.6 Nanoscale assembly
may pre-concentrate their toxic conformations, which on
microbial membranes would instantaneously convert intoMiddlesex, TW11 0LW, UK. E-mail: max.
rtments of Biochemical Engineering and
ondon, London WC1E 6BT, UK
ESI) available: Materials and methods,
c and X-ray scattering data. See DOI:
hemistry 2016membrane-destabilising pores. The nanostructures are thus
akin to antimicrobial projectiles that bypass the need for
membrane-induced folding and destroy microbial membranes
on direct contact. With this in mind, we set out to combine the
eﬃciency of viral assembly and gene-delivery with the anti-
microbial responsiveness of host-defense peptides into one
self-assembling motif.
Our design rationale uses three main principles. Firstly, the
motif should assemble into nanoscale virus-like capsules with
and without nucleic acids. This is to ensure the autonomous
functioning of the capsules independent of cargo, which can
vary. Secondly, the capsules have to be appreciably antimicro-
bial. This is necessary for fast and localised antimicrobial
responses. Thirdly, the capsules must promote active gene
transfer into mammalian cells without causing cytotoxic and
haemolytic eﬀects. An overarching principle for all three is the
structural plasticity of the capsules without a priori require-
ments for a particular size.
Based on these conventions, we reviewed an antimicrobial
and non-haemolytic protein lactoferrin. This is a major
component of the innate immune system found in secretory
uids including saliva and milk and is notably responsible for
providing antimicrobial protection to infants. The antimicro-
bial activity of this protein is attributed to a core sequence of six
amino acids – RRWQWR (Fig. 1a).7 In its free, isolated form the
peptide is moderately antimicrobial and does not assemble.
The sequence is homologues to virus-derived tryptophan
zippers, with a characteristic core motif WTW, which adopts b-
turn and b-sheet conformations with cross-strand tryptophan
rings packed tightly against one another.8 b-Strands, arranged
antiparallel, foster interactions between amino-acid side chains
of opposite termini.Chem. Sci., 2016, 7, 1707–1711 | 1707
Fig. 2 Capzip assembly with and without siRNA. (a) TEM (left) and
cryo-SEM (right) images of assembled capsules. Collapsed capsules
are highlighted by white squares. (b) In-air AFM topography images of
capsules of diﬀerent sizes and their 3D representations. Colour bars
are 20 nm (upper) and 60 nm (lower). (c) Cross-section ﬂuorescence
micrographs of a large capsule with gradual depth changes (0.1–0.2
mm). (d) TEM (left) and AFM (middle) images of capsules assembled
with siRNA. Capsule sizes with (+) and without () siRNA measure by
high-res TEM. Assembly conditions: 100 mM peptide, 1/5 N/P (siRNA–
peptide) molar ratio, pH 7.4, MOPS, 20 C, overnight.
Fig. 1 Capzip design. (a) Antimicrobial lactoferrin peptide (PDB entry
1LFC rendered by PyMol) with the RRWQWR motif highlighted in blue
(top). The motif is converted to a self-complementary RRWTWE b-
strand (bottom). (b) Three copies of RRWTWE are conjugated into a b-
strand triskelion. For clarity only two triskelions forming a b-sheet are
shown and highlighted in diﬀerent colours. (c) Triskelions self-
assemble via a b-sheet-formation following a trilateral honeycomb-
like symmetry. (d) The chemical structure of the triskelion. (e) A b-
strand triskelion model with arginine and tryptophan residues high-
lighted by blue and yellow, respectively.
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To capitalize on this, the glutamine and C-terminal arginine of
the lactoferrin motif were replaced with threonine and gluta-
mate giving rise to a self-complementary sequence RRWTWE
(Fig. 1a and b). With the virus architecture adopting an n-fold
rotational symmetry, where n is usually 3 or 5 or both,9 a triskel
conjugate of RRWTWE was generated to give a self-assembling
motif with a trilateral symmetry reminiscent of native cage-like
subunits (Fig. 1b–e and S1 in ESI†).
The resulting construct, dubbed capzip, readily assembled
into morphologically uniform and hollow capsules with domi-
nating size ranges of 20–200 nm, as seen by transmission
electron microscopy (TEM), atomic force microscopy (AFM) and
cryo-scanning electron microscopy (SEM) (Fig. 2, S2a and b†).
Larger assemblies were also observed suggesting thermody-
namically equilibrated paracrystalline systems (Fig. 2a–c and
S2c†).10 Paracrystals oen exhibit regular nanoscale patterns
such as striations or rings.11,12 Although ne structure could be
observed on some capsules, this appeared irregular (Fig. 2a),
which may imply a larger structural plasticity than that for
perfectly crystalline materials.13 In the triskel conjugate,
RRWTWE is prone to fold as a b-turn and pair into a b-sheet
with another arm of another conjugate.7 Triskelions are then
expected to propagate into two-dimensional sheets whose
increasing curvature would facilitate the formation of three-
dimensional capsules (Fig. 1c).
Consistent with this, circular dichroism (CD) spectra for capzip
were characteristic of b-turns, withminima at l 200 nm and 214
nm, containing elements of a b-sheet structure and indole1708 | Chem. Sci., 2016, 7, 1707–1711transitions of the tryptophan residues (Fig. 3a).7,8,14 Fourier
transform infrared (FT-IR) spectra conrmed the structure with
bands at 1660 and 1545 cm1, and at 1535 and 1562 cm1 for the
de-convoluted amide II region corresponding to b-sheet and b-
turn conformations, respectively (Fig. 3b).15 These ndings infer
that intra-molecular hydrogen bonds in the core of each conjugate
(b-turn) complement inter-molecular hydrogen bonding between
the arms of diﬀerent conjugates (b-sheet).
Such synergy between folding and assembly manifested in
a compact globular morphology of the capsules observed by
AFM in solution (Fig. S3†). Complementary evidence was
provided by the cross-sectional analysis of the assembled
capsules using uorescence microscopy. Fluorescein, used to
label capzip, incorporated exclusively in the walls of the
capsules revealing an inner cavity (Fig. 2c and S2c†). Small angle
X-ray scattering (SAXS) measurements, which can provide
a direct probe of supramolecular assemblies in solution, re-
emphasised the synergy: SAXS curves obtained with a charac-
teristic Porod's dependence (I  q4) in the terminal regions
were consistent with compact capsules interfacing with the
solvent (Fig. 3c).16
Combined the results support the capsule-like assembly of
capzip as per the design rationale. To assess the functionalThis journal is © The Royal Society of Chemistry 2016
Fig. 3 Capzip folding with and without siRNA. (a) CD spectra for
capzip (solid line) and capzip with siRNA (30 mM, dashed line). (b) FT-IR
spectra for capzip: raw spectrum (black line), cumulative ﬁt (dotted
blue line), deconvoluted amide I spectrum (pink line) and amide II
spectra (green and orange lines). Folding conditions: 100 mM peptide,
pH 7.4, 10mMMOPS, 20 C. (c) SAXS curves for capzip (200 mM, black),
siRNA (20 mM, red) and capzip–siRNA (1/10 N/P molar ratio, blue). (d)
Diﬀerential absorbance (DA) at 210 nm versus N/P molar ratio derived
from CD titration spectra for capzip (100 mM).
Fig. 4 Capzip-promoted gene delivery and silencing. (a) Fluorescence
micrographs of HeLa cells expressing green ﬂuorescent protein used
as internal background ﬂuorescence for Alex647-labelled siRNA, at 1/5
N/P (siRNA–peptide) molar ratios. (b) Knockdown ﬁtness of capzip and
commercial Lipofectamine® RNAiMAX and N-TER® (positive
controls) normalised against siRNA alone (negative control) and the
total counts of viable cells at diﬀerent N/P (siRNA–peptide) molar
ratios.
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View Article Onlinerelevance of the design the capsules were probed for their ability
to (i) enable gene transport and (ii) exert rapid and localized
antimicrobial responses. Regarding (i), the capsules were pro-
bed to deliver small interfering RNAs (siRNAs), which are
promising tools for RNA interference (RNAi) devised to inhibit
targeted gene expression. However, siRNAs are easily degrad-
able, cannot cross cellular membranes and require constant
protection and guided delivery, which hampers further prog-
ress.17 Capzip oﬀers an exploitable solution.
The design was found to readily co-assemble with model
siRNAs (21 bp duplexes) into structures that were similar to bare
capsules (Fig. 2d and S2d†). CD spectra of these assemblies
contained characteristic features of the A-DNA form, which were
more profound for higher siRNA ratios, including a positive
Cotton eﬀect at 260–270 nm and maxima at 210 nm and
190 nm (Fig. 3a). SAXS data was consistent with the CD results
and for siRNA alone showed the expected double-helix dimen-
sions of 2.3  5 nm (Fig. 3c). Signals recorded for capzip with
and without siRNA were similar. However, the signals were
distinctive from those for siRNA alone suggesting that siRNA
incorporates without aﬀecting the original capsule topology and
is eﬃciently packed by the peptide assembly (Fig. 3c).18 siRNA
aﬃnity to capzip (Kd ¼ 3.25  0.88 mM) was in expected ranges
for peptide–RNA complexes (Fig. 3d, S4a and b†),19,20 while N/P
molar ratios at 1/10 matched those obtained as saturation
points by agarose gel electrophoresis (Fig. S4c†).
At these ratios capzip promoted an active siRNA delivery
within the rst hours, with particulate cytoplasmic spreads of
uorescent siRNA suggesting an endocytic uptake. The spreads
were stable over the rst ve hours of incubation whereupon
uorescence was not observed (Fig. 4a). These characteristicsThis journal is © The Royal Society of Chemistry 2016were comparable to those of other transfection reagents21 and
conform to the RNAi rationale aimed at transient gene
silencing.17 To gain a quantitative insight into this, we moni-
tored knockdown at the mRNA level using a HeLa cell line with
two housekeeping genes, ACTB (b-actin, targeted) and GAPDH
(reference).22 The silencing of b-actin mRNA was detected at
22  2 hours post-transfection. Knockdown “tness” was
expressed relative to cells treated with siRNA alone (back-
ground) and normalised against viable cell counts (Fig. 4b).
Lipofectamine® used as a positive control showed higher
knockdown levels compared to capzip but this was at the
expense of substantially reduced cell numbers indicating
apparent cytotoxicity.23 Indeed, Alamar Blue® cell proliferation
and viability assays, which are quantitative redox indicators of
metabolically active cells, revealed impaired cell viability for the
control reagents (Fig. S5†). By contrast, cells transfected with
capzip at diﬀerent transfection concentrations remained viable
over 24 and 48 hours (Fig. S5†). No obvious increases in
knockdown were observed for capzip at higher peptide
concentrations suggesting that N/P ratios close to equimolar are
suﬃcient for siRNA uptake and that the peptide does not
aﬀect cell viability. In contrast to lipofectamine, which
undergoes non-specic fusion with cell membranes, capzip is
rich in arginines and tryptophans, known for profound cell-Chem. Sci., 2016, 7, 1707–1711 | 1709
Fig. 5 Capzip-promoted antimicrobial activity and mechanism. (a) Confocal micrographs of bacterial cells after 16 hour incubations with and
without capzip, stained with membrane-permeant SYTO®9. White histogram bars denote total cell counts (%) for bacterial colonization with
capzip after subtracting background adhesion taken as 100%. (b) AFM topography of SLBs during capzip incubation in solution. White boxes and
arrows highlight individual capsule conversions into pores. Color scale is 6 nm. Cross sections show the evolution of a capsule (white arrow in
inset images) into a pore in real time. (c) Representative cross-sections of capsules and pores.
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View Article Onlinepenetrating24 and membrane fusion25 properties, which render
the capsules intrinsically transfecting. Because capzip proved to
be non-toxic, but has antimicrobial propensity, it was deemed
appropriate here to address the earlier point (ii).
Capzip was found antimicrobial in bacterial culture, with
minimum inhibitory concentrations (MICs) typical of other
antimicrobial agents (Table S1†). The MICs were comparable to
the transfection concentrations of capzip, non-toxic to human
cells. To relate MICs to antimicrobial responses at the cellular
level we sought complementary evidence from stain-dead assays
using planktonic bacterial culture as a measure of total cell
counts with and without capzip. Marginal counts for capzip-
treated samples were in drastic contrast to substantial bacterial
colonisation for incubations without peptide (Fig. 5a). The
ndings support sustained antimicrobial activity and, with no
hemolytic eﬀects detected (Table S1†), reect the diﬀerential
plasticity of capzip in cellular environments, likely involving
fast and localised disruption of microbial membranes.
To probe this in suﬃcient detail, we measured membrane
disruption in supported lipid bilayers (SLBs) used as models for
uid-phase bacterial membranes that can be imaged in solution
and in real time.6 As gauged by AFM, capzip caused distinctive
pore-like lesions in SLBs within just rst minutes of incubation
(Fig. 5b). The pore depths of 1.8  0.4 nm were remarkably1710 | Chem. Sci., 2016, 7, 1707–1711consistent, while their diameters correlated with those of
observed capsules (31  3 nm) (Fig. 5c). Notably, individual
capsules tended to convert into individual pores at their precise
landing positions, with conversion times being 3–17 min. Such
fast and localised responses prompt a distinctive mechanism
according to which arginines and tryptophans pre-arrange in
the capsules into amphipathic cationic b-strands that penetrate
lipid bilayers at one-strand depths, 2 nm (0.3 nm translation
per b-sheet residue), as capsules land and collapse on
membrane surfaces thereby converting into pore and lesions
(Fig. 5b and Video S1†).
Conclusions
In summary, we have introduced a conceptual design for virus-
like capsules with diﬀerential biological activity. Similar to
viruses, the capsules self-assemble from individual subunits
and promote gene delivery and silencing. Unlike viruses, for
which monodispersity in size is a necessary constraint ensuring
the encapsulation of viral genes, the capsules are not limited to
hosting specic cargo and are structurally plastic. This allows
them to attack bacterial cells on direct contact. With most
bacteria having 0.2  #2 mm dimensions, 0.02–1 mm capsules
match the task perfectly. Rigid viral capsids cannot readilyThis journal is © The Royal Society of Chemistry 2016
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View Article Onlineaccommodate or adjust to encapsulate diﬀerent cargo or more
of the same cargo. Capzip capsules are free of such constraints
and can be utilised to deliver a range of cargo while providing
antimicrobial protection. Thus, the concept holds promise as
a structural platform for engineering biologically diﬀerential
nanomaterials and adds to the growing toolkit of nano-dened
materials26–28 demonstrating the versatility of applied chemistry
and design.Acknowledgements
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